RxDoctor Payments Data

Carlos Smith, MD

Internal Medicine · Key Largo, FLNPI 1427008226

Payments from drug & device makers

$611in general payments, 2019–2025

Across 22 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$83
  • Novartis$75
  • Welch Allyn$66
  • Braemar Manufacturing, LLC$58
  • Amgen$52
  • Biomerieux Inc$41
  • plus $235 from 9 others

What the payments were for

  • Food & beverage$54589%
  • Other$6611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$83
Novartis3$75
Welch Allyn1$66
Braemar Manufacturing, LLC1$58
Amgen2$52
Biomerieux Inc1$41
Novo Nordisk2$39
Lilly USA, LLC2$33
Eisai Inc.1$32
Tempus AI, Inc1$29
Alvogen Inc1$28
Exact Sciences1$24
Radius Health, Inc.1$20
Watermark Medical, Inc.1$17
Pfizer1$13

How this compares

$611 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$200,547
Medicare patients
311
Services billed
3,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$95,377
EliquisApixaban61$89,326
OzempicSemaglutide46$50,300
XareltoRivaroxaban23$37,985
Repatha SureclickEvolocumab11$17,286
MyrbetriqMirabegron14$14,017
VascepaIcosapent Ethyl13$11,577
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,172
ArexvyRsvpref3 Antigen/As01e/Pf11$3,403
Atorvastatin Calcium196$2,702
Candesartan Cilexetil26$2,314
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid11$2,136
Rosuvastatin Calcium114$1,872
Ezetimibe29$1,189
Levothyroxine Sodium79$983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$33$95,37780 claims
PfizerEliquis$13$89,32661 claims
Novo NordiskOzempic$39$50,30046 claims
GSKShingrix, Arexvy$83$7,57530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Key Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →